186 related articles for article (PubMed ID: 23272659)
1. Unsupported off-label chemotherapy in metastatic colon cancer.
de Souza JA; Polite B; Perkins M; Meropol NJ; Ratain MJ; Newcomer LN; Alexander GC
BMC Health Serv Res; 2012 Dec; 12():481. PubMed ID: 23272659
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
5. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
Hradecká I; Ríhová B; Horová R; Demlová R
Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
[TBL] [Abstract][Full Text] [Related]
6. Evolving treatment of advanced colon cancer.
Segal NH; Saltz LB
Annu Rev Med; 2009; 60():207-19. PubMed ID: 19630571
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
8. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
9. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
[No Abstract] [Full Text] [Related]
10. Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
Seal BS; Anderson S; Shermock KM
J Manag Care Spec Pharm; 2016 Mar; 22(3):227-35. PubMed ID: 27003552
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS
J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
Eng C
Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946
[TBL] [Abstract][Full Text] [Related]
13. [A review of chemotherapy for metastatic colon cancer].
Díez-Fernández R; Salinas Hernández P; Girón-Duch C
Farm Hosp; 2006; 30(6):359-69. PubMed ID: 17298193
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
15. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
16. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Int J Clin Oncol; 2010 Jun; 15(3):256-62. PubMed ID: 20198398
[TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
Croom KF; Dhillon S
Drugs; 2011 Nov; 71(16):2213-29. PubMed ID: 22035518
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Delea TE; Tappenden P; Sofrygin O; Browning D; Amonkar MM; Karnon J; Walker MD; Cameron D
Eur J Health Econ; 2012 Oct; 13(5):589-603. PubMed ID: 21701940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]